These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Revisiting the Function of CDK7 in Transcription by Virtue of a Recently Described TFIIH Kinase Inhibitor. Coin F; Egly JM Mol Cell; 2015 Aug; 59(4):513-4. PubMed ID: 26295956 [TBL] [Abstract][Full Text] [Related]
3. Human TFIIH Kinase CDK7 Regulates Transcription-Associated Chromatin Modifications. Ebmeier CC; Erickson B; Allen BL; Allen MA; Kim H; Fong N; Jacobsen JR; Liang K; Shilatifard A; Dowell RD; Old WM; Bentley DL; Taatjes DJ Cell Rep; 2017 Aug; 20(5):1173-1186. PubMed ID: 28768201 [TBL] [Abstract][Full Text] [Related]
4. Cyclin-dependent kinase control of the initiation-to-elongation switch of RNA polymerase II. Larochelle S; Amat R; Glover-Cutter K; Sansó M; Zhang C; Allen JJ; Shokat KM; Bentley DL; Fisher RP Nat Struct Mol Biol; 2012 Nov; 19(11):1108-15. PubMed ID: 23064645 [TBL] [Abstract][Full Text] [Related]
5. The CDK7 inhibitor THZ1 alters RNA polymerase dynamics at the 5' and 3' ends of genes. Sampathi S; Acharya P; Zhao Y; Wang J; Stengel KR; Liu Q; Savona MR; Hiebert SW Nucleic Acids Res; 2019 May; 47(8):3921-3936. PubMed ID: 30805632 [TBL] [Abstract][Full Text] [Related]
6. TFIIH-associated Cdk7 kinase functions in phosphorylation of C-terminal domain Ser7 residues, promoter-proximal pausing, and termination by RNA polymerase II. Glover-Cutter K; Larochelle S; Erickson B; Zhang C; Shokat K; Fisher RP; Bentley DL Mol Cell Biol; 2009 Oct; 29(20):5455-64. PubMed ID: 19667075 [TBL] [Abstract][Full Text] [Related]
7. CDK7 kinase activity promotes RNA polymerase II promoter escape by facilitating initiation factor release. Velychko T; Mohammad E; Ferrer-Vicens I; Parfentev I; Werner M; Studniarek C; Schwalb B; Urlaub H; Murphy S; Cramer P; Lidschreiber M Mol Cell; 2024 Jun; 84(12):2287-2303.e10. PubMed ID: 38821049 [TBL] [Abstract][Full Text] [Related]
8. THZ1 targeting CDK7 suppresses c-KIT transcriptional activity in gastrointestinal stromal tumours. Sun J; Zhang Q; Sun X; Xue A; Gao X; Shen K Cell Commun Signal; 2022 Sep; 20(1):138. PubMed ID: 36076237 [TBL] [Abstract][Full Text] [Related]
9. Inhibition of cyclin-dependent kinase 7 suppresses human hepatocellular carcinoma by inducing apoptosis. Zhong L; Yang S; Jia Y; Lei K J Cell Biochem; 2018 Dec; 119(12):9742-9751. PubMed ID: 30145799 [TBL] [Abstract][Full Text] [Related]
10. CDK7 inhibition as a promising therapeutic strategy for lung squamous cell carcinomas with a SOX2 amplification. Hur JY; Kim HR; Lee JY; Park S; Hwang JA; Kim WS; Yoon S; Choi CM; Rho JK; Lee JC Cell Oncol (Dordr); 2019 Aug; 42(4):449-458. PubMed ID: 30838525 [TBL] [Abstract][Full Text] [Related]
11. Nanomaterial-Facilitated Cyclin-Dependent Kinase 7 Inhibition Suppresses Gallbladder Cancer Progression via Targeting Transcriptional Addiction. Huang CS; Xu QC; Dai C; Wang L; Tien YC; Li F; Su Q; Huang XT; Wu J; Zhao W; Yin XY ACS Nano; 2021 Sep; 15(9):14744-14755. PubMed ID: 34405985 [TBL] [Abstract][Full Text] [Related]
12. CDK7 inhibitor THZ1 inhibits MCL1 synthesis and drives cholangiocarcinoma apoptosis in combination with BCL2/BCL-XL inhibitor ABT-263. Huang T; Ding X; Xu G; Chen G; Cao Y; Peng C; Shen S; Lv Y; Wang L; Zou X Cell Death Dis; 2019 Aug; 10(8):602. PubMed ID: 31399555 [TBL] [Abstract][Full Text] [Related]
13. THZ1 reveals CDK7-dependent transcriptional addictions in pancreatic cancer. Lu P; Geng J; Zhang L; Wang Y; Niu N; Fang Y; Liu F; Shi J; Zhang ZG; Sun YW; Wang LW; Tang Y; Xue J Oncogene; 2019 May; 38(20):3932-3945. PubMed ID: 30692639 [TBL] [Abstract][Full Text] [Related]
14. CDK7 inhibitor THZ1 enhances antiPD-1 therapy efficacy via the p38α/MYC/PD-L1 signaling in non-small cell lung cancer. Wang J; Zhang R; Lin Z; Zhang S; Chen Y; Tang J; Hong J; Zhou X; Zong Y; Xu Y; Meng R; Xu S; Liu L; Zhang T; Yang K; Dong X; Wu G J Hematol Oncol; 2020 Jul; 13(1):99. PubMed ID: 32690037 [TBL] [Abstract][Full Text] [Related]
15. The Covalent CDK7 Inhibitor THZ1 Potently Induces Apoptosis in Multiple Myeloma Cells Zhang Y; Zhou L; Bandyopadhyay D; Sharma K; Allen AJ; Kmieciak M; Grant S Clin Cancer Res; 2019 Oct; 25(20):6195-6205. PubMed ID: 31358538 [TBL] [Abstract][Full Text] [Related]
16. CDK7 Inhibition is Effective in all the Subtypes of Breast Cancer: Determinants of Response and Synergy with EGFR Inhibition. McDermott MSJ; Sharko AC; Munie J; Kassler S; Melendez T; Lim CU; Broude EV Cells; 2020 Mar; 9(3):. PubMed ID: 32155786 [TBL] [Abstract][Full Text] [Related]
17. CDK7 inhibition suppresses aberrant hedgehog pathway and overcomes resistance to smoothened antagonists. Liu F; Jiang W; Sui Y; Meng W; Hou L; Li T; Li M; Zhang L; Mo J; Wang J; Zhao Y; Zhang L; Ma J; Tang Y Proc Natl Acad Sci U S A; 2019 Jun; 116(26):12986-12995. PubMed ID: 31182587 [TBL] [Abstract][Full Text] [Related]
18. CDK7 inhibition by THZ1 suppresses cancer stemness in both chemonaïve and chemoresistant urothelial carcinoma via the hedgehog signaling pathway. Chow PM; Chang YW; Kuo KL; Lin WC; Liu SH; Huang KH Cancer Lett; 2021 Jun; 507():70-79. PubMed ID: 33741425 [TBL] [Abstract][Full Text] [Related]
19. Separable functions of the fission yeast Spt5 carboxyl-terminal domain (CTD) in capping enzyme binding and transcription elongation overlap with those of the RNA polymerase II CTD. Schneider S; Pei Y; Shuman S; Schwer B Mol Cell Biol; 2010 May; 30(10):2353-64. PubMed ID: 20231361 [TBL] [Abstract][Full Text] [Related]
20. Cdk7: a kinase at the core of transcription and in the crosshairs of cancer drug discovery. Fisher RP Transcription; 2019 Apr; 10(2):47-56. PubMed ID: 30488763 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]